A novel drug-based AQP4-specific inhibitor, TGN-020, was shown to decrease tau and p-tau clearance, implicating faulty AQP4 in tau accumulation and suggesting that the glymphatic system could be a druggable target for AD treatment and possibly other NDs as well [53]. Here, AQP4 is linked to Alzheimer disease.